Regulus Therapeutics
RGLS
#7200
Rank
โ‚ฌ0.51 B
Marketcap
7,44ย โ‚ฌ
Share price
0.00%
Change (1 day)
464.48%
Change (1 year)

Regulus Therapeutics (RGLS) - Total liabilities

Total liabilities on the balance sheet as of March 2025 : โ‚ฌ5.28 Million

According to Regulus Therapeutics's latest financial reports the company's total liabilities are โ‚ฌ5.28 Million. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Regulus Therapeutics - Total liabilities on balance sheet (from 2011 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚ฌ7.46 M-13.65%
2023-12-31โ‚ฌ8.65 M-30.88%
2022-12-31โ‚ฌ12.51 M5.02%
2021-12-31โ‚ฌ11.91 M26.6%
2020-12-31โ‚ฌ9.41 M-52.21%
2019-12-31โ‚ฌ19.69 M-33.29%
2018-12-31โ‚ฌ29.52 M-16.82%
2017-12-31โ‚ฌ35.49 M-16.25%
2016-12-31โ‚ฌ42.38 M172.55%
2015-12-31โ‚ฌ15.55 M-52.07%
2014-12-31โ‚ฌ32.45 M51.36%
2013-12-31โ‚ฌ21.43 M-31.54%
2012-12-31โ‚ฌ31.31 M-51.8%
2011-12-31โ‚ฌ64.97 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Sanofi
SNY
โ‚ฌ61.89 B 1,171,014.18%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚ฌ12.06 B 228,230.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ59.58 B 1,127,323.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ59.67 B 1,128,961.75%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚ฌ64.49 B 1,220,115.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
โ‚ฌ71.94 M 1,261.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚ฌ4.00 B 75,629.91%๐Ÿ‡บ๐Ÿ‡ธ USA